Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Square Brussels Convention Centre

Mar 12, 2024 9:00 AM - Mar 14, 2024 4:00 PM

Glass Entrance, Mont des Arts/Kunstberg, 1000 Brussels, Belgium

DIA Europe 2024

EU Regulatory Townhall: The New Pharmaceutical Legislation – How Are We Setting the Stage for Availability and Access of Novel Healthcare Solutions?

Session Chair(s)

Steffen  Thirstrup, MD, PHD

Steffen Thirstrup, MD, PHD

Chief Medical Officer, European Medicines Agency, Netherlands

The New Pharmaceutical legislation sets out ways to increase availability, access and affordability of medicines (“triple A”). The European Medicines Agency is already actively implementing the Regulatory Science Strategy and European Medicines Regulatory Network Strategy to 2025 and beyond. These strategies address the triple A challenge, with increased dialogue with patients and healthcare professionals, HTA and payers, as well as embracing new technologies, influencing and facilitating development of highly innovative medicines and treatment. Hear from the European Commission, European Medicines Agency, HMA, patient representatives, pharmaceutical industry and HTA. Are regulators on the right track with the strategies they have set out to enable access and availability of medicines? Share your views on opportunities arising from current significant changes in the European ecosystem and anticipating the impact of the “triple A” political objectives in the new pharma legislation. Debate with us what success looks like in delivering on those!

Learning Objective : - understand legal process and parallel activities - understand implications of the legal changes on EMA and the regulatory system for centrally authorised medicines

Speaker(s)

Rainer  Becker

Rainer Becker

Director, European Commission, DG Health & Food Safety, Belgium

Emer  Cooke, MBA, MSC

Emer Cooke, MBA, MSC

Chair, ICMRA; Executive Director, European Medicines Agency, Netherlands

Karl  Broich, DrMed

Karl Broich, DrMed

President, Federal Institute for Drugs and Medical Devices (BfArM), Germany

Sabine  Atzor, MPHARM, RPH

Sabine Atzor, MPHARM, RPH

Head of EU Regulatory Policies, F. Hoffmann-La Roche Ltd, Switzerland

New EU Pharma Legislation - Implementation Ahead?

Christine  Kampf, MS

Christine Kampf, MS

Executive Director of Regulatory Affairs, Marinus Pharma, United States

Niklas  Hedberg, MPHARM

Niklas Hedberg, MPHARM

HTACG Co-Chair & Chief Pharmacist, Dental and Pharmaceutical Benefits Agency, TLV, Sweden

Nikos  Dedes

Nikos Dedes

Representative, European AIDS Treatment Group (EATG), Greece

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.